New shot for chronic hives begins safety testing

NCT ID NCT06604949

Ongoing Disease control Sponsor: Longbio Pharma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a single dose of LP-003, a new drug for chronic spontaneous urticaria (long-lasting hives), in 12 healthy adults. The main goal is to check safety and how the body processes the drug. It is not yet tested in people with hives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LP-003
What this could lead to: If safe, this could lead to a new treatment option for chronic hives, helping control symptoms.
What could go wrong: This is a very early Phase 1 trial with only 12 healthy people, not patients. It tests safety only, not effectiveness. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA

Contacts and locations

Locations

Shanghai General Hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.